Mechanisms of asthma and allergic inflammationBlocking IL-25 prevents airway hyperresponsiveness in allergic asthma
Section snippets
Mice
BALB/c mice were obtained from Harlan UK (Bicester, UK) and maintained in the Small Animal Barrier Unit and Central Biomedical Services or National Heart and Lung Institute facilities in specific pathogen-free environments. il4–/–il5–/–il9–/–il13–/– mice and il13–/– mice on a BALB/c background (6th generation backcross) were as described.1, 16Il25–/– mice on a C57BL/6 × 129 background were as described.11 All animal experiments outlined in this report were undertaken with the approval of the UK
Generation of blocking anti–rmIL-25 mAbs
To study the biology of IL-25, we generated anti–IL-25 mAbs by immunizing il25–/– mice with rmIL-25. Two of these anti–IL-25 antibodies (2C3 and 5C1) blocked the interaction between rmIL-25 and a soluble mouse IL-25R-Fc fusion protein dose-dependently (data not shown) and inhibited IL-25–dependent production of IL-13 by primary mouse non-B, non-T cells in an in vitro bioassay (data not shown).
Neutralization of IL-25 during sensitization and airway challenge prevents development of allergic airway inflammation and AHR
Our studies and those of others suggest that IL-25 acts upstream of the type 2 cytokines and that by
Discussion
Using an antagonist of IL-25 to block IL-25 bioactivity, our data highlight for the first time the critical and functionally distinct roles played by endogenous IL-25 in a mouse model of allergic asthma. We have shown that IL-25 acts first at the initiation of the type 2 cytokine–dependent induction of airway inflammation, but also plays an essential role in the development of AHR independently of the inflammatory response, through both IL-13–dependent and independent pathways.
When administered
References (24)
- et al.
IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13
Immunity
(2002) - et al.
IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo
Immunity
(2001) - et al.
Transgenic overexpression of human IL-17E results in eosinophilia, B-lymphocyte hyperplasia, and altered antibody production
Blood
(2002) - et al.
Interleukin-17 family and IL-17 receptors
Cytokine Growth Factor Rev
(2003) - et al.
IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1
J Biol Chem
(2001) - et al.
Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation
Blood
(2003) - et al.
A distinct role for interleukin-13 in Th2-cell-mediated immune responses
Curr Biol
(1998) - et al.
IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice
J Allergy Clin Immunol
(2006) - et al.
IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts
J Allergy Clin Immunol
(2006) - et al.
Genetic linkage of T-cell receptor alpha/delta complex to specific IgE responses
Lancet
(1994)
Requirement for IL-13 independently of IL-4 in experimental asthma
Science
Interleukin-13: central mediator of allergic asthma
Science
Cited by (329)
T-helper 2 mechanisms involved in human rhinovirus infections and asthma
2022, Annals of Allergy, Asthma and ImmunologyPharmacological approaches to target type 2 cytokines in asthma
2022, Pharmacology and TherapeuticsWhat has been learned by cytokine targeting of asthma?
2022, Journal of Allergy and Clinical ImmunologyCitation Excerpt :IL-25 can augment downstream T2 cytokine expansion, including IL-4, IL-5 and IL-13, and increase IgE level and eosinophil count. IL-25 inhibition in mouse models of allergic asthma diminishes recruitment of eosinophils and other TH2-polarizing cells to the airway and abrogates IL-5, IL-13, and IgE levels and AHR.90 Like the effects of TSLP, these IL-25 effects have the potential to regulate T2-dependent asthma.
Supported by a grant from the Medical Research Council of Great Britain and Asthma UK.
Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.